Cougar Biotechnology Reports Positive Data on CB7630
LOS ANGELES—Cougar Biotechnology, Inc.'s CB7630 (abiraterone acetate) was well tolerated at doses as high as 2,000 mg/d with minimal toxicity in a phase I/II trial of chemotherapy-naive patients with castration-refractory prostate cancer, who had progressive disease despite treatment with LHRH analogs and multiple other hormonal therapies. Of 30 evaluable patients, 18 (60%) had a confirmed decline in PSA of greater than 50%, while 10 (33%) had declines greater than 90%. Of 20 evaluable patients with measurable lesions, 11 (55%) had a partial radiological response, while 7 had ongoing stable disease and 3 had regressing bone disease. The data were presented at the American Urological Association (AUA) annual meeting.
LOS ANGELESCougar Biotechnology, Inc.'s CB7630 (abiraterone acetate) was well tolerated at doses as high as 2,000 mg/d with minimal toxicity in a phase I/II trial of chemotherapy-naive patients with castration-refractory prostate cancer, who had progressive disease despite treatment with LHRH analogs and multiple other hormonal therapies. Of 30 evaluable patients, 18 (60%) had a confirmed decline in PSA of greater than 50%, while 10 (33%) had declines greater than 90%. Of 20 evaluable patients with measurable lesions, 11 (55%) had a partial radiological response, while 7 had ongoing stable disease and 3 had regressing bone disease. The data were presented at the American Urological Association (AUA) annual meeting.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
